Identification new biomarkers by multistage fragmentation spectra – Prof. Ron A Vewers, Translational Metabolic Laboratory, Radboud University Medical Centre, Nijmegen, the Netherlands
Metabolic tracing of purine de novo biosynthesis by mass spectrometry, Ing. Marie Zikánová, Ph.D., Charles University in Prague, Czech Republic.
Metabolomics and lipidomics of tauopathies – Dr. Andrej Kovac, Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Lung cancer tissue metabolomics, Prof. Michal Holčapek, Department of Analytical Chemistry Pardubice, Faculty of Chemical Technology, University of Pardubice, Czech Republic.
Metabolomic/lipidomic analysis of mice samples with glutamate carboxypeptidase II deficiency, Dr. Barbora Vorlová, Charles University of Prague, Czech Republic.
Metabolomic/lipidomic analysis of DBS from patients with short chain acyl-CoA dehydrogenase deficiency, Banská Bystrica Children’s University Hospital, Slovakia.
Metabolomic/lipidomic analysis of sweat from patients with breast cancer, Prof. MUDr. Zdeněk Zadák, CSc., University Hospital Hradec Králové, Czech Republic.
Statistical tools development – Prof. P Filzmoser, Department of Statistics and Probability Theory, Vienna University of Technology, Vienna, Austria.
Plasma metabolic profiling of asthmatic and cystic fibrosis mice models – Prof. D Radzioch, Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
Metabolite profiling of serum, DBS and urine from horses with atypical myopathy – MVDr. Petr Jahn, CSc., Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic.
The most important past projects of the laboratory
Biomedicine for regional development and human resources. In collaboration with the Institute of Organic Chemistry and Biochemistry AS CR, v.v.i., Prague, Czech Republic; and the Institute of Chemical Technology, Prague, Czech Republic
Diagnostic tools of inherited diseases of purine and pyrimidine metabolism. In collaboration with Dr A H Simmonds (Purine Research Laboratory, Guy’s Hospital, London, UK);
Development of treatment of Diamond-Blackfan anemia patients. In collaboration with Professor D Pospisilova (Department of Paediatrics, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Czech Republic)
Personalised treatment of chronic myeloproliferative disorders and myelodysplastic syndrome – a cellular metabolomics study. In collaboration with Novartis International AG and Professor E Faber (Department of Haemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Czech Republic)
Studies of genes and molecular mechanisms involved in regulation of haematopoiesis, their clinical impact and targeted treatment. In collaboration with Professor K Indrak (Department of Haemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Czech Republic)
Novel biochemical markers for various types of cancer. In collaboration with Professor B Melichar (Department of Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Czech Republic);
Disease mechanism of ADSL patients;
Molecular and biochemical cystinuria study. In collaboration with Dr L Kozák, (Faculty Hospital, Brno, Czech Republic) and Dr S Stastna (Institute for Inherited Metabolic Diseases, Charles University in Prague, Czech Republic)
The role of cellular transport mechanisms in efficacy of imatinib mesylate treatment in patients with chronic myeloid leukaemia. In collaboration with Dr V Divoky (Department of Biology, Faculty of Medicine and Dentistry, Palacky University, Czech Republic);
Diagnosing inherited metabolic disorders by metabolomic approaches. Norwegian University of Science and Technology (Norges teknisk-naturvitenskapelige universitet, NTNU Trondheim, Norway) and SINTEF (Oslo, Norway); and
Defects of de novo synthesis of purines – metabolic study. In collaboration with David A Patterson (Department of Biological Sciences, University of Denver, USA).
Prediction of orthogonality for comprehensive two-dimensional separations by second dimension retention indices – Prof. J-M Dimandja, Spelman College, Atlanta, Georgia, USA.
Mass spectrometry tools development for untargeted metabolomics – Thermo Fisher Scientific, San Jose, Silicon Valley, CA, USA.
Defining disease mechanisms and treatment response of chronic myeloid leukaemia by metabolomics; High throughput method for therapeutic drug monitoring and drug metabolisation study – Prof. Edgar Faber, Department of Hemato-Oncology, University Hospital Olomouc, Faculty of Medicine and Dentistry, Palacky University, Czech Republic.
Improving technologies for metabolomics and software robots decision algorithms – Dr R Mistrik, HighChem Ltd., Bratislava, Slovakia.